New Ventures III

Enterin Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments that address the gut-brain axis in relation to neurodegenerative diseases. The company is advancing its lead product, ENT-01, which aims to reverse constipation associated with Parkinson's disease by displacing aggregates of alpha-synuclein in nerve cells. This mechanism is designed to enhance neural signaling between the gut and the brain, potentially improving outcomes for patients. Enterin also explores synthetic derivatives of endogenous hormones to target misfolded proteins linked to various conditions, including Alzheimer's disease and Type 2 diabetes. Founded in 2014 and based in Philadelphia, Pennsylvania, Enterin seeks to delay the onset and progression of neurodegenerative disorders while contributing to a better understanding of aging and its related pathologies.

Transparency Life Sciences, LLC is a drug development company based in New York that utilizes crowdsourcing and mobile health technology to enhance the clinical trial process for biopharmaceutical candidates. Founded in 2012, the company aims to improve patient relevance and efficiency in clinical trials by adopting an all-digital model that shifts away from traditional site-centric methodologies. This innovative approach addresses the dissatisfaction of drug sponsors who seek better-designed, technologically advanced, and more cost-effective trials. By leveraging digital advancements and regulatory support, Transparency Life Sciences strives to transform the clinical trial landscape, enabling the development of more therapies that are currently overlooked due to inefficiencies in existing processes. With the clinical trial services market projected to grow significantly, the company's scalable model positions it to address the pressing needs of the biopharma industry.

Enterin Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments that address the gut-brain axis in relation to neurodegenerative diseases. The company is advancing its lead product, ENT-01, which aims to reverse constipation associated with Parkinson's disease by displacing aggregates of alpha-synuclein in nerve cells. This mechanism is designed to enhance neural signaling between the gut and the brain, potentially improving outcomes for patients. Enterin also explores synthetic derivatives of endogenous hormones to target misfolded proteins linked to various conditions, including Alzheimer's disease and Type 2 diabetes. Founded in 2014 and based in Philadelphia, Pennsylvania, Enterin seeks to delay the onset and progression of neurodegenerative disorders while contributing to a better understanding of aging and its related pathologies.